Alumis Inc.
ALMS
Ранг среди акций
#10408
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Цена акции
$6.15
Последняя синхронизация: 2026-10-16
Рыночная капитализация
$795.38M
Изменение (1 день)
-2.61%
Изменение (1 год)
170.70%
Страна
US
Торговля Alumis Inc. (ALMS)
Категория
Healthcare
EPS для Alumis Inc. (ALMS)
EPS по состоянию на March 2025 TTM: $-2.70
Согласно последним финансовым отчетам и цене акций Alumis Inc., текущий EPS компании (TTM) составляет $-2.70. В конце 2023 EPS компании составлял $-5.43, больше, чем показателю 2022 года, равному $-0.70.
История EPS компании Alumis Inc. с 2021 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2026 (TTM) | $-2.70 | 8.00% |
| 2024 | $-2.50 | -53.96% |
| 2023 | $-5.43 | 675.71% |
| 2022 | $-0.70 | -65.85% |
| 2021 | $-2.05 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $17.32 | -741.48% |
US
|
|
| $-7.98 | 195.56% |
US
|
|
| $-5.29 | 95.93% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,127.41% |
NL
|
